<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research : BCR</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">bcr2200</article-id><article-id pub-id-type="pmid">19025652</article-id><article-id pub-id-type="doi">10.1186/bcr2200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A functional <italic>Notch</italic>&#x02013;<italic>survivin </italic>gene signature in basal breast cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Lee</surname><given-names>Connie W</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>connie.lee@umassmed.ed</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Simin</surname><given-names>Karl</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karl.simin@umassmed.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Liu</surname><given-names>Qin</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>qin.liu@umassmed.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Plescia</surname><given-names>Janet</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>janet.plescia@umassmed.edu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Guha</surname><given-names>Minakshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>minakshi.guha@umassmed.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Khan</surname><given-names>Ashraf</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ashraf.khan@umassmed.edu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Hsieh</surname><given-names>Chung-Cheng</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chung-cheng.hsieh@umassmed.edu</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>Altieri</surname><given-names>Dario C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dario.altieri@umassmed.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA</aff><aff id="I2"><label>2</label>Department of Medicine, Preventive and Behavioral Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA</aff><aff id="I3"><label>3</label>Department of Pathology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA</aff><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>24</day><month>11</month><year>2008</year></pub-date><volume>10</volume><issue>6</issue><fpage>R97</fpage><lpage>R97</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/10/6/R97"/><history><date date-type="received"><day>21</day><month>7</month><year>2008</year></date><date date-type="rev-request"><day>27</day><month>8</month><year>2008</year></date><date date-type="rev-recd"><day>12</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Lee et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Lee et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Lee W Connie connie.lee@umassmed.ed </dc:author><dc:title> A functional Notch&#x02013;survivin gene signature in basal breast cancer </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Breast Cancer Research 10(6): R97-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-5411(2008)10:6&#x0003c;R97&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-5411</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Basal-type, or triple-negative, breast cancer (lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression) is a high-risk disease for which no molecular therapies are currently available. We studied genetic signatures of basal breast cancer potentially suitable for therapeutic intervention.</p></sec><sec sec-type="methods"><title>Methods</title><p>We analyzed protein expression of the Notch-1 intracellular domain and survivin by immunohistochemistry in a series of basal breast cancer patients. A hierarchical clustering and overall survival analysis was carried out on a microarray mRNA database of 232 breast cancer patients. Fifteen published mRNA datasets containing estrogen receptor-negative or estrogen receptor-positive samples were subjected to meta-analysis for co-segregated gene expression. Experiments of plasmid transfection and gene silencing were carried out in estrogen receptor-negative MDA-MB-231 breast cancer cells.</p></sec><sec><title>Results</title><p>The developmental signaling regulator Notch-1 was highly expressed in breast cancer, compared with normal tissue, and was segregated with basal disease. Higher <italic>Notch-1 </italic>levels correlated with progressively abbreviated overall survival, and with increased expression of <italic>survivin</italic>, a tumor-associated cell death and mitotic regulator implicated in stem cell viability. Analysis of Pearson's correlation coefficient indicated that <italic>Notch-1 </italic>and <italic>survivin </italic>co-segregated in basal breast cancer. Notch-1 stimulation in MDA-MB-231 cells increased survivin expression, whereas silencing Notch reduced survivin levels.</p></sec><sec><title>Conclusions</title><p>A <italic>Notch-1&#x02013;survivin </italic>functional gene signature is a hallmark of basal breast cancer, and may contribute to disease pathogenesis. Antagonists of Notch and survivin currently in the clinic may be tested as novel molecular therapy for these recurrence-prone patients.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>The introduction of molecular gene signatures in breast cancer provides important prognostic and predictive information [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>], and holds promise for individualized molecular therapy of these patients [<xref ref-type="bibr" rid="B4">4</xref>]. Certain subtypes of breast cancer, however, continue to pose therapeutic challenges [<xref ref-type="bibr" rid="B4">4</xref>]. For example, basal breast cancer is a myoepithelial disease variant characterized by high histologic grade [<xref ref-type="bibr" rid="B5">5</xref>], by the absence of HER-2 (ErB2) and receptors for estrogen and progesterone [<xref ref-type="bibr" rid="B6">6</xref>], by the expression of basal cytokeratins (that is, keratin 5) and proliferation-associated genes [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], as well as by defects in genomic gatekeepers, p53, or BRCA1 [<xref ref-type="bibr" rid="B9">9</xref>]. While immunohistochemical diagnosis of basal breast cancer is straightforward [<xref ref-type="bibr" rid="B6">6</xref>], these patients have limited therapeutic options: the response to mainstay chemotherapy is not uniform and is affected by the type of drugs used [<xref ref-type="bibr" rid="B10">10</xref>]; estrogen or HER-2 targeting is not indicated; and attempts to disable ancillary signaling pathways, for instance coordinated by the epidermal growth factor receptor, have so far shown little promise [<xref ref-type="bibr" rid="B11">11</xref>]. This adds to a high rate of relapses, which in several series has been linked to shortened overall survival and to death from disease [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Although the cell of origin of basal breast cancer has not been conclusively identified [<xref ref-type="bibr" rid="B5">5</xref>], a link to the progenitor/stem cell compartment of the mammary epithelium has been proposed [<xref ref-type="bibr" rid="B13">13</xref>]. In this context, developmental gene expression pathways that control the interplay between cell proliferation, survival, and differentiation are candidates for stem cell-derived mammary tumorigenesis [<xref ref-type="bibr" rid="B14">14</xref>]. One such pathway is centered on the Notch family of cell surface receptors [<xref ref-type="bibr" rid="B15">15</xref>] &#x02013; which affects the mammary stem cell niche [<xref ref-type="bibr" rid="B16">16</xref>], and has been associated with malignant transformation [<xref ref-type="bibr" rid="B17">17</xref>] and aggressive tumor behavior [<xref ref-type="bibr" rid="B18">18</xref>]. Notch expression is correlated to human breast cancer formation but the downstream pathways that guide such behavior are still under investigation [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Among the candidate effector molecules controlling stem cell viability is survivin, a dual regulator of cell division and apoptosis, broadly overexpressed in cancer [<xref ref-type="bibr" rid="B21">21</xref>]. Consistent with its onco-fetal pattern of expression, survivin is essential for tissue homeostasis [<xref ref-type="bibr" rid="B21">21</xref>] &#x02013; and conditional knockout studies have suggested a potential critical role of this pathway in maintaining stem cell viability, at least in certain tissue compartments [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>In the present study, we used a combination of hierarchical clustering and overall survival analysis of a novel microarray dataset, meta-analysis of published gene profiling studies, and cell culture experiments to investigate a potential role of a Notch-1&#x02013;survivin signaling axis in breast cancer.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Immunohistochemistry</title><p>Nine cases of basal breast cancers with associated clinical and pathological data were obtained from the archives of the Department of Pathology, University of Massachusetts Medical School. Analysis of anonymous discarded tissue with no patient identifiers was approved by and in compliance with Institutional Review Board guidelines.</p><p>Tissue sections (5 &#x003bc;m) were cut from paraffin blocks, deparaffinized in xylene, rehydrated, and baked overnight at 60&#x000b0;C. Slides were quenched for endogenous peroxidase with 3% H<sub>2</sub>O<sub>2 </sub>in methanol for 20 minutes, and were processed for antigen retrieval by pressure cooking in 9 mM sodium citrate, pH 6.0, for 20 minutes. Slides were washed in PBS, and incubated overnight at 4&#x000b0;C with a rabbit antibody to the Notch-1 intracellular domain (NIC) or control IgG, were rinsed, and were further incubated with a biotinylated anti-rabbit IgG for 10 minutes at 22&#x000b0;C. After addition of streptavidin-conjugated horseradish peroxidase, the slides were incubated with 3',3'-diamino-benzidine for 3 to 10 minutes, and were counterstained with hematoxylin, as described previously [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Hierarchical clustering analysis of Notch-1 mRNA expression in breast cancer</title><p>The log<sub>2 </sub>Cy5/Cy3 ratios of 232 cases of human breast cancer and their associated clinical data were downloaded from the University of North Carolina Microarray Database [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Only genes where the Lowess normalized intensity values in both channels were &#x0003e; 30 and data existed in &#x0003e; 70% samples were included for analysis. The gene set was further filtered to include only genes with Pearson's correlation coefficient &#x0003e; 0.58 with <italic>Notch-1 </italic>(n = 101).</p><p>Two-way hierarchical clustering was performed using Cluster v3 [<xref ref-type="bibr" rid="B26">26</xref>], and the results were displayed using JavaTreeview [<xref ref-type="bibr" rid="B27">27</xref>]. Analysis of overall survival (log-rank test) was carried out using JMP 6.0 [<xref ref-type="bibr" rid="B28">28</xref>] (SAS Institute, Cary, NC, USA) on the subset of breast cancer patients in this cohort with available clinical data (n = 125). Data were plotted for each quartile of normalized <italic>Notch-1 </italic>log<sub>2 </sub>ratios, from highest (first quartile) to lowest (fourth quartile). The breast cancer patients were further divided into basal (n = 35) or nonbasal (n = 88) subgroups and were analyzed for overall survival (log-rank test) using JMP 6.0 [<xref ref-type="bibr" rid="B28">28</xref>].</p></sec><sec><title>Meta-analysis of Oncomine microarray data</title><p>We reviewed Oncomine [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>] for independent human breast cancer microarray datasets comparing estrogen receptor (ER)-negative and ER-positive tumors. Databases from 15 studies were found to contain <italic>Notch-1 </italic>and <italic>survivin </italic>relative expression data. The patient characteristics and analyses performed in each study are summarized in Table <xref ref-type="table" rid="T1">1</xref>. Descriptive statistics including the mean, standard error, and a two-tailed unpaired <italic>t </italic>test were calculated for the comparisons between ER-positive and ER-negative samples within each study. Separately for ER-negative and ER-positive samples, a Pearson's correlation coefficient (<italic>r</italic>) was calculated for each study to measure levels of pair-wise co-expression between <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5</italic>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Published datasets included in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Study</td><td align="left"><italic>n</italic></td><td align="left">Median age (years)</td><td align="left">Microarray</td><td align="left">Tumor size</td><td align="left">Lymph nodes (LN)</td><td align="left">Treatment</td><td align="left">Stage/grade</td></tr></thead><tbody><tr><td align="left">Chin and colleagues [<xref ref-type="bibr" rid="B55">55</xref>]</td><td align="left">118</td><td align="left">55.3 (SD = 14.3)</td><td align="left">Affymetrix</td><td align="left">2.6 cm (SD = 1.3)</td><td align="left">67 LN-positive, 51 LN-negative</td><td align="left">60% tamoxifen, 52% adjuvant chemotherapy, 51% radiation</td><td align="left">26 stage 1, 70 stage 2, 14 stage 3, 5 stage 4; 10 grade 1, 42 grade 2, 61 grade 3; 5 unknown</td></tr><tr><td align="left">Desmedt and colleagues [<xref ref-type="bibr" rid="B56">56</xref>]</td><td align="left">198</td><td align="left">47 (all &#x0003c; 61)</td><td align="left">Affymetrix</td><td align="left">&#x0003c; 5 cm</td><td align="left">Node-negative</td><td></td><td align="left">T1&#x02013;T2</td></tr><tr><td align="left">Ginestier and colleagues [<xref ref-type="bibr" rid="B57">57</xref>]</td><td align="left">55</td><td></td><td align="left">Affymetrix</td><td></td><td></td><td align="left">19 amplified for 20q13, 36 unamplified for 20q13</td><td align="left">Consecutive cases, unilateral localized invasive breast cancer</td></tr><tr><td align="left">Hess and colleagues [<xref ref-type="bibr" rid="B58">58</xref>]</td><td align="left">133</td><td align="left">Training set, 52 (range 29 to 79); validation set, 50 (range 28 to 73)</td><td align="left">Affymetrix</td><td></td><td></td><td align="left">Preoperative weekly paclitaxel and fluorouracil&#x02013;doxorubicin&#x02013;cyclophosphamide chemotherapy</td><td align="left">Stage I, stage II, stage III</td></tr><tr><td align="left">Ivshina and colleagues [<xref ref-type="bibr" rid="B59">59</xref>]</td><td align="left">249 (Uppsala cohort)</td><td align="left">62.3</td><td align="left">Affymetrix</td><td align="left">2.9 cm</td><td align="left">35% node-positive</td><td align="left">30.3% endocrine therapy, 10.7% chemotherapy, 1.7% combination therapy, 58.8% no systemic therapy</td><td align="left">68 grade 1, 126 grade 2, 55 grade 3</td></tr><tr><td align="left">Miller and colleagues [<xref ref-type="bibr" rid="B60">60</xref>]</td><td align="left">251</td><td align="left">62.1 (SD = 13.9)</td><td align="left">Affymetrix</td><td align="left">22.4 mm (SD = 12.5)</td><td align="left">84/253 LN metastasis, 160 node-negative, 9 unknown node status</td><td align="left">143 no adjuvant therapy; others with systemic adjuvant therapy, and/or chemotherapy</td><td></td></tr><tr><td align="left">Minn and colleagues [<xref ref-type="bibr" rid="B61">61</xref>]</td><td align="left">82</td><td align="left">55.8 (SD = 13.5)</td><td align="left">Affymetrix</td><td align="left">3.68 cm (SD = 1.77 cm)</td><td align="left">Average 3.5 (SD = 5.98) axillary LN</td><td align="left">Adjuvant chemotherapy and/or hormonal therapy</td><td></td></tr><tr><td align="left">Richardson and colleagues [<xref ref-type="bibr" rid="B62">62</xref>]</td><td align="left">39</td><td></td><td align="left">Affymetrix</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Saal and colleagues [<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left">105</td><td align="left">61 (range 26 to 77)</td><td align="left">Non-Affymetrix</td><td align="left">27 mm (range 2 to 50 mm)</td><td align="left">65 (62%) LN-positive</td><td align="left">Treated uniformly with 2 years of adjuvant tamoxifen</td><td align="left">Stage II, primary breast cancer</td></tr><tr><td align="left">Sotiriou and colleagues [<xref ref-type="bibr" rid="B63">63</xref>]</td><td align="left">119 (KJ125 dataset)</td><td align="left">45% &#x0003c; 50, 55% &#x0003e; 50</td><td align="left">Affymetrix</td><td align="left">61% &#x0003c; 2 cm, 39% &#x0003e; 2 cm</td><td align="left">LN-negative</td><td align="left">No adjuvant systemic therapy</td><td align="left">34 grade 1, 46 grade 2, 28 grade 3, 17 not available</td></tr><tr><td align="left">Turashvili and colleagues [<xref ref-type="bibr" rid="B32">32</xref>]</td><td align="left">10</td><td></td><td align="left">Affymetrix</td><td></td><td></td><td></td><td align="left">3 grade I, 5 grade II, 2 grade III</td></tr><tr><td align="left">van de Vijver and colleagues [<xref ref-type="bibr" rid="B64">64</xref>]</td><td align="left">295</td><td align="left">&#x0003c; 52</td><td align="left">Non-Affymetrix</td><td align="left">&#x0003c; 5 cm</td><td align="left">151 LN-negative, 144 LN-positive</td><td align="left">Modified radical mastectomy or breast-conserving surgery</td><td align="left">Stage I or stage II breast cancer</td></tr><tr><td align="left">Wang and colleagues [<xref ref-type="bibr" rid="B65">65</xref>]</td><td align="left">286</td><td align="left">54 (SD = 12)</td><td align="left">Affymetrix</td><td></td><td align="left">LN-negative</td><td align="left">No adjuvant treatment</td><td></td></tr><tr><td align="left">Yu and colleagues [<xref ref-type="bibr" rid="B38">38</xref>]</td><td align="left">96 (only 68 with Notch-1 and survivin data)</td><td align="left">55 (SD = 10.9)</td><td align="left">Affymetrix</td><td align="left">37.7 mm (SD = 17.9)</td><td align="left">37.5% LN-negative</td><td></td><td align="left">2 unknown grade, 5 grade I, 26 grade II, 63 grade III</td></tr><tr><td align="left">Zhao and colleagues [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left">59 (35 intraductal carcinoma, 17 intralobular carcinoma; three from each with unknown ER status)</td><td align="left">Ductal, 53 (SD = 15.5); lobular, 63.5 (SD = 14.0)</td><td align="left">Non-Affymetrix</td><td></td><td align="left">Ductal, 16 LN-positive, 16 LN-negative, 3 LN unknown; lobular, 7 LN-positive, 7 LN-negative, 4 LN unknown</td><td></td><td align="left">Ductal, 5 grade I, 19 grade II, 11 grade III; lobular, 17 grade II, 1 grade I</td></tr></tbody></table><table-wrap-foot><p>Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study criteria.</p></table-wrap-foot></table-wrap><p>The 95% confidence interval for <italic>r </italic>was calculated based on Fisher's <italic>Z </italic>transformation [<xref ref-type="bibr" rid="B31">31</xref>]. In one study a Fisher's <italic>Z </italic>transformation could not be performed for ER-negative samples (n = 3) [<xref ref-type="bibr" rid="B32">32</xref>], and an approximate variance for a Pearson's correlation coefficient was used to derive its 95% confidence interval. To summarize ER-specific results from the individual studies, Fisher's <italic>Z </italic>transformation and its variance were used in pooling correlation from different studies. The weighted average of Fisher's <italic>Z </italic>transformation and its 95% confidence interval were first estimated based on a fixed-effect model, taking into account the variance associated with each study. The ER-specific pooled estimate of Pearson's correlation coefficient and its 95% confidence interval were then derived from the estimates based on the Fisher's <italic>Z </italic>transformation. We applied a random-effect model for meta-analysis [<xref ref-type="bibr" rid="B33">33</xref>] to evaluate whether levels of co-expressions between <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5 </italic>differ between ER-negative and ER-positive samples among the different studies.</p></sec><sec><title>Cells, reagents and transfections</title><p>The breast adenocarcinoma MDA-MB-231 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA), and was maintained in culture as recommended by the supplier. The cDNA encoding activated NIC was characterized previously [<xref ref-type="bibr" rid="B34">34</xref>]. MDA-MB-231 cells were transfected with control plasmid cDNA or NIC cDNA (2 &#x003bc;g) using 6 &#x003bc;l LipofectAmine (Invitrogen, Carlsbad, CA, USA) in Opti-Mem medium (1 ml) (Gibco, Carlsbad, CA, USA). The media was changed after 5 hours, and cells were harvested after 24 hours.</p><p>The peptidyl &#x003b3;-secretase inhibitor z-Leu-Leu-Nle-CHO was purchased from Calbiochem (San Diego, CA, USA), and has been characterized previously [<xref ref-type="bibr" rid="B35">35</xref>]. For gene silencing experiments by siRNA, MDA-MB-231 cells were transfected with double-stranded RNA oligonucleotide directed to Notch-1 (pool of three siRNA; Santa Cruz, Santa Cruz, CA, USA), survivin, or control nontargeted sequences using 10 &#x003bc;l HiPerfect (Gibco). Cells under the various conditions were harvested after 48 hours, and were analyzed by western blotting.</p></sec></sec><sec><title>Results</title><sec><title>Expression of Notch-1 and survivin in basal breast cancer</title><p>Recent studies have shown that Notch activation results in increased expression of survivin in basal breast cancer cell lines [<xref ref-type="bibr" rid="B35">35</xref>]. To determine whether a similar association occurs <italic>in vivo</italic>, we examined by immunohistochemistry a panel of basal breast cancer cases for expression of activated Notch-1 (NIC) and survivin. The average age of the nine patients was 52.3 &#x000b1; 6.1 years. All cases were grade 3 tumors with negative protein expression of ER, progesterone receptor, and HER-2, and positive protein expression of keratin 5/6, as assessed by immunohistochemistry. Activated Notch-1 was abundantly expressed in all cases examined of basal breast cancer, and was localized to both the cytosol and nuclei of tumor cells (Figure <xref ref-type="fig" rid="F1">1</xref>). Survivin was also strongly expressed in all basal breast cancer cases, and was similarly localized to the nuclei and cytosol of the tumor cell population (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Expression of activated Notch-1 and survivin in basal breast cancer. Representative basal breast cancer cases were analyzed by immunohistochemistry. NIC, Notch-1 intracellular domain.</p></caption><graphic xlink:href="bcr2200-1"/></fig></sec><sec><title>Expression of Notch-1 mRNA in breast cancer microarray databases</title><p>We next analyzed the expression of Notch-1 mRNA in an established breast cancer patient cohort. Supervised hierarchical clustering of 232 cases of human breast cancer [<xref ref-type="bibr" rid="B25">25</xref>], using intrinsic gene analysis, revealed that higher expression of <italic>Notch-1 </italic>segregated with basal breast cancer. Other known markers of the disease, including <italic>keratin-5</italic>, <italic>keratin-14</italic>, and <italic>kit</italic>, were also highly correlated with <italic>Notch-1 </italic>expression (<italic>r </italic>&#x02265; 0.58) in this cohort (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><italic>Notch-1 </italic>segregates with basal breast cancer. Heat map of 232 cases of breast cancer. Unclassified, gray; normal breast-like, green; luminal A, light blue; luminal B, dark blue; HER-2+/estrogen receptor-negative (ER-), purple; basal, red.</p></caption><graphic xlink:href="bcr2200-2"/></fig><p>One hundred and twenty-five patients with associated clinical outcome data were further analyzed. When stratified according to levels of <italic>Notch-1 </italic>log<sub>2 </sub>transcript ratios, tumors with the highest quartile of <italic>Notch-1 </italic>gene expression (first quartile) exhibited abbreviated overall survival with a median survival of 27 months compared with the other groups (<italic>P </italic>&#x0003c; 0.001 via the log-rank test) (Figure <xref ref-type="fig" rid="F3">3a</xref>). Seventy-two percent of tumors in this first quartile (23/32 tumors) were classified as basal breast cancer, and the overall survival of these patients was approximately 50% lower of that of the remaining population (<italic>P </italic>&#x0003c; 0.02). Conversely, reduced levels of <italic>Notch-1 </italic>(second to fourth quartiles) were associated with better overall survival (Figure <xref ref-type="fig" rid="F3">3a</xref>). The percentage of basal breast cancers in these groups was 17% (second quartile, 5/30 tumors), 20% (third quartile, 6/30 tumors), and 10% (fourth quartile, 3/31 tumors), respectively.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Overall survival. <bold>(a) </bold>Kaplan&#x02013;Meier curves of differential overall survival were plotted according to Notch-1 expression in the entire cohort (quartiles). <bold>(b) </bold>Nonbasal tumors and <bold>(c) </bold>basal tumors were subgrouped into high Notch-1 expression (fourth quartile) or low Notch-1 expression (first to third quartiles) and were analyzed for overall survival.</p></caption><graphic xlink:href="bcr2200-3"/></fig><p>The tumors were then segregated based on basal or nonbasal subgroup status and were analyzed for overall survival. In the nonbasal breast tumors, the expression of <italic>Notch-1 </italic>was not associated with significant differences in overall survival (<italic>P </italic>= 0.2734) (Figure <xref ref-type="fig" rid="F3">3b</xref>). In contrast, <italic>Notch-1 </italic>levels dictated overall survival in basal breast tumors (Figure <xref ref-type="fig" rid="F3">3c</xref>). In this basal subgroup, increased <italic>Notch-1 </italic>expression (fourth quartile) greatly reduced overall survival to the median of 26 months (Figure <xref ref-type="fig" rid="F3">3c</xref>). Comparatively, low levels of <italic>Notch-1 </italic>(first to third quartiles) demonstrated improved overall survival (Figure <xref ref-type="fig" rid="F3">3c</xref>).</p></sec><sec><title>Gene expression correlation in basal breast cancer</title><p>We next carried out a meta-analysis of published microarray datasets to identify genes associated with Notch and potentially implicated in the molecular pathogenesis of basal breast cancer. Based on our recent data [<xref ref-type="bibr" rid="B35">35</xref>], we focused on <italic>survivin </italic>&#x02013; a mitotic regulator and cell death inhibitor overexpressed in breast cancer [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B21">21</xref>], and associated with unfavorable outcome [<xref ref-type="bibr" rid="B2">2</xref>] &#x02013; and <italic>keratin-5 </italic>&#x02013; a marker of basal epithelium, often linked to a progenitor/stem cell phenotype [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Fifteen microarray datasets, mostly employing Affymetrix technology, published between 2002 and 2007 met the search criteria (Table <xref ref-type="table" rid="T1">1</xref>). The overall median age of patients was 55.2 years. The breast tumors examined were typically &#x0003c; 5 cm, encompassing all grades, and included lymph node-positive and lymph node-negative disease. In one study, separate databases for lobular and ductal breast cancer were examined [<xref ref-type="bibr" rid="B36">36</xref>] &#x02013; bringing the datasets analyzed to a total of 16. Two studies did not contain downloadable <italic>keratin-5 </italic>expression data [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>], and one study contained 68 out of 96 samples with <italic>Notch-1 </italic>and <italic>survivin </italic>data and 19 samples with <italic>keratin-5 </italic>data [<xref ref-type="bibr" rid="B38">38</xref>]. Table <xref ref-type="table" rid="T2">2</xref> presents the descriptive statistics of each cohort with respect to <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5 </italic>relative expression.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Descriptive statistics of studies in the meta-analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Study</td><td align="left">Total <italic>n</italic></td><td align="left">Subset</td><td align="center" colspan="3">Survivin</td><td align="center" colspan="3">Notch-1</td><td align="center" colspan="3">Keratin 5</td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="left">Mean</td><td align="left">SEM</td><td align="left"><italic>P</italic></td><td align="left">Mean</td><td align="left">SEM</td><td align="left"><italic>P</italic></td><td align="left">Mean</td><td align="left">SEM</td><td align="left"><italic>P</italic></td></tr></thead><tbody><tr><td align="left">Chin and colleagues [<xref ref-type="bibr" rid="B55">55</xref>]</td><td align="left">118</td><td align="left">ER- (n = 43)</td><td align="left">0.7723</td><td align="left">0.0815</td><td align="left">1.353 &#x000d7; 10<sup>-5</sup></td><td align="left">0.7793</td><td align="left">0.0548</td><td align="left">2.231 &#x000d7; 10<sup>-5</sup></td><td align="left">0.9844</td><td align="left">0.1436</td><td align="left">4.893 &#x000d7; 10<sup>-6</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 75)</td><td align="left">0.3371</td><td align="left">0.0437</td><td></td><td align="left">0.5027</td><td align="left">0.0245</td><td></td><td align="left">0.1884</td><td align="left">0.0678</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Desmedt and colleagues [<xref ref-type="bibr" rid="B56">56</xref>]</td><td align="left">198</td><td align="left">ER- (n = 64)</td><td align="left">0.7238</td><td align="left">0.0478</td><td align="left">1.414 &#x000d7; 10<sup>-8</sup></td><td align="left">0.3254</td><td align="left">0.0389</td><td align="left">3.951 &#x000d7; 10<sup>-4</sup></td><td align="left">0.6649</td><td align="left">0.0996</td><td align="left">1.159 &#x000d7; 10<sup>-2</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 134)</td><td align="left">0.3278</td><td align="left">0.0460</td><td></td><td align="left">0.1658</td><td align="left">0.0193</td><td></td><td align="left">0.3773</td><td align="left">0.0507</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Ginestier and colleagues [<xref ref-type="bibr" rid="B57">57</xref>]</td><td align="left">55</td><td align="left">ER- (n = 28)</td><td align="left">0.7621</td><td align="left">0.1251</td><td align="left">9.689 &#x000d7; 10<sup>-5</sup></td><td align="left">1.4343</td><td align="left">0.0504</td><td align="left">2.933 &#x000d7; 10<sup>-4</sup></td><td align="left">1.2587</td><td align="left">0.2116</td><td align="left">1.219 &#x000d7; 10<sup>-2</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 27)</td><td align="left">0.4959</td><td align="left">0.0954</td><td></td><td align="left">1.1536</td><td align="left">0.0520</td><td></td><td align="left">0.5842</td><td align="left">0.1492</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Hess and colleagues [<xref ref-type="bibr" rid="B58">58</xref>]</td><td align="left">133</td><td align="left">ER- (n = 51)</td><td align="left">0.0776</td><td align="left">0.0451</td><td align="left">2.071 &#x000d7; 10<sup>-3</sup></td><td align="left">0.2169</td><td align="left">0.0454</td><td align="left">1.203 &#x000d7; 10<sup>-1</sup></td><td align="left">0.5110</td><td align="left">0.1706</td><td align="left">1.165 &#x000d7; 10<sup>-4</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 82)</td><td align="left">-0.0956</td><td align="left">0.0309</td><td></td><td align="left">0.1238</td><td align="left">0.0384</td><td></td><td align="left">-0.2216</td><td align="left">0.0480</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Ivshina and colleagues [<xref ref-type="bibr" rid="B59">59</xref>]</td><td align="left">249<sup>a</sup></td><td align="left">ER- (n = 34)</td><td align="left">0.4877</td><td align="left">0.0847</td><td align="left">1.064e &#x000d7; 10<sup>-7</sup></td><td align="left">0.3819</td><td align="left">0.0589</td><td align="left">1.643 &#x000d7; 10<sup>-2</sup></td><td align="left">0.7071</td><td align="left">0.1683</td><td align="left">1.403 &#x000d7; 10<sup>-1</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 211)</td><td align="left">-0.0950</td><td align="left">0.0408</td><td></td><td align="left">0.2299</td><td align="left">0.0137</td><td></td><td align="left">0.4438</td><td align="left">0.0479</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Miller and colleagues [<xref ref-type="bibr" rid="B60">60</xref>]</td><td align="left">251</td><td align="left">ER- (n = 34)</td><td align="left">0.3701</td><td align="left">0.0681</td><td align="left">2.780 &#x000d7; 10<sup>-8</sup></td><td align="left">0.3011</td><td align="left">0.0443</td><td align="left">2.073 &#x000d7; 10<sup>-2</sup></td><td align="left">0.4714</td><td align="left">0.1310</td><td align="left">2.638 &#x000d7; 10<sup>-1</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 213)</td><td align="left">-0.1337</td><td align="left">0.0382</td><td></td><td align="left">0.1905</td><td align="left">0.0113</td><td></td><td align="left">0.3165</td><td align="left">0.0389</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Minn and colleagues [<xref ref-type="bibr" rid="B61">61</xref>]</td><td align="left">82</td><td align="left">ER- (n = 42)</td><td align="left">0.1969</td><td align="left">0.0719</td><td align="left">1.809 &#x000d7; 10<sup>-4</sup></td><td align="left">0.4515</td><td align="left">0.0529</td><td align="left">7.897 &#x000d7; 10<sup>-5</sup></td><td align="left">1.1060</td><td align="left">0.1311</td><td align="left">2.391 &#x000d7; 10<sup>-6</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 57)</td><td align="left">-0.1821</td><td align="left">0.0652</td><td></td><td align="left">0.2036</td><td align="left">0.0247</td><td></td><td align="left">0.2624</td><td align="left">0.1028</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Richardson and colleagues [<xref ref-type="bibr" rid="B62">62</xref>]</td><td align="left">39</td><td align="left">ER- (n = 24)</td><td align="left">-0.1141</td><td align="left">0.1363</td><td align="left">6.374 &#x000d7; 10<sup>-3</sup></td><td align="left">1.1360</td><td align="left">0.0621</td><td align="left">1.216 &#x000d7; 10<sup>-1</sup></td><td align="left">1.1878</td><td align="left">0.1436</td><td align="left">4.670e &#x000d7; 10<sup>-3</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 15)</td><td align="left">-0.6187</td><td align="left">0.1089</td><td></td><td align="left">1.0139</td><td align="left">0.0457</td><td></td><td align="left">0.6193</td><td align="left">0.1225</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Saal and colleagues [<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left">105</td><td align="left">ER- (n = 60)</td><td align="left">-1.3798</td><td align="left">0.1075</td><td align="left">5.143 &#x000d7; 10<sup>-6</sup></td><td align="left">0.2043</td><td align="left">0.0756</td><td align="left">3.033 &#x000d7; 10<sup>-3</sup></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 45)</td><td align="left">-2.1290</td><td align="left">0.1121</td><td></td><td align="left">-0.1145</td><td align="left">0.0728</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Sotiriou and colleagues [<xref ref-type="bibr" rid="B63">63</xref>]</td><td align="left">119</td><td align="left">ER- (n = 34)</td><td align="left">0.4834</td><td align="left">0.0320</td><td align="left">2.528 &#x000d7; 10<sup>-3</sup></td><td align="left">0.2702</td><td align="left">0.0565</td><td align="left">1.323 &#x000d7; 10<sup>-4</sup></td><td align="left">0.9849</td><td align="left">0.1107</td><td align="left">9.396 &#x000d7; 10<sup>-3</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 85)</td><td align="left">0.3691</td><td align="left">0.0166</td><td></td><td align="left">0.0181</td><td align="left">0.0196</td><td></td><td align="left">0.6560</td><td align="left">0.0499</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Turashvili [<xref ref-type="bibr" rid="B32">32</xref>]</td><td align="left">10</td><td align="left">ER- (n = 3)</td><td align="left">0.1268</td><td align="left">0.1688</td><td align="left">2.533 &#x000d7; 10<sup>-1</sup></td><td align="left">1.1991</td><td align="left">0.1243</td><td align="left">3.082 &#x000d7; 10<sup>-1</sup></td><td align="left">0.6117</td><td align="left">0.3735</td><td align="left">6.750 &#x000d7; 10<sup>-1</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 7)</td><td align="left">-0.2686</td><td align="left">0.2733</td><td></td><td align="left">1.0239</td><td align="left">0.0709</td><td></td><td align="left">0.3655</td><td align="left">0.4358</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">van de Vijver and colleagues [<xref ref-type="bibr" rid="B64">64</xref>]</td><td align="left">295</td><td align="left">ER- (n = 69)</td><td align="left">0.3719</td><td align="left">0.2218</td><td align="left">1.847 &#x000d7; 10<sup>-12</sup></td><td align="left">0.6277</td><td align="left">0.1148</td><td align="left">1.418 &#x000d7; 10<sup>-10</sup></td><td align="left">-0.7917</td><td align="left">0.4073</td><td align="left">1.748 &#x000d7; 10<sup>-5</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 226)</td><td align="left">-1.7301</td><td align="left">0.1580</td><td></td><td align="left">-0.2900</td><td align="left">0.0590</td><td></td><td align="left">-2.8083</td><td align="left">0.1822</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Wang and colleagues [<xref ref-type="bibr" rid="B65">65</xref>]</td><td align="left">286</td><td align="left">ER- (n = 77)</td><td align="left">0.0902</td><td align="left">0.0459</td><td align="left">2.284 &#x000d7; 10<sup>-8</sup></td><td align="left">0.4139</td><td align="left">0.0282</td><td align="left">2.255 &#x000d7; 10<sup>-11</sup></td><td align="left">0.8906</td><td align="left">0.0819</td><td align="left">3.242 &#x000d7; 10<sup>-7</sup></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 209)</td><td align="left">-0.2387</td><td align="left">0.0318</td><td></td><td align="left">0.1784</td><td align="left">0.0151</td><td></td><td align="left">0.3844</td><td align="left">0.0459</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Yu and colleagues [<xref ref-type="bibr" rid="B38">38</xref>]</td><td align="left">68 (19)</td><td align="left">ER- (n = 15)</td><td align="left">-0.2546</td><td align="left">0.0874</td><td align="left">1.689 &#x000d7; 10<sup>-1</sup></td><td align="left">-0.2712</td><td align="left">0.1090</td><td align="left">1.946 &#x000d7; 10<sup>-4</sup></td><td align="left">1.8394*</td><td align="left">0.2312*</td><td align="left">2.280 &#x000d7; 10<sup>-2 </sup>*</td></tr><tr><td></td><td></td><td align="left">ER+ (n = 4)</td><td align="left">-0.4225</td><td align="left">0.0831</td><td></td><td align="left">0.7625</td><td align="left">0.0431</td><td></td><td align="left">0.9196*</td><td align="left">0.2431*</td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Zhao and colleagues (lobular) [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left">16</td><td align="left">ER- (n = 4)</td><td align="left">-2.4418</td><td align="left">0.2721</td><td align="left">6.851 &#x000d7; 10<sup>-1</sup></td><td align="left">0.0416</td><td align="left">0.4079</td><td align="left">7.011 &#x000d7; 10<sup>-1</sup></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 12)</td><td align="left">-2.3108</td><td align="left">0.1269</td><td></td><td align="left">-0.1367</td><td align="left">0.1083</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="12"></td></tr><tr><td align="left">Zhao and colleagues (ductal) [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left">34</td><td align="left">ER- (n = 11)</td><td align="left">-1.4613</td><td align="left">0.2938</td><td align="left">1.440 &#x000d7; 10<sup>-1</sup></td><td align="left">0.3298</td><td align="left">0.3722</td><td align="left">1.769 &#x000d7; 10<sup>-1</sup></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="left">ER+ (n = 23)</td><td align="left">-2.0013</td><td align="left">0.1981</td><td></td><td align="left">-0.2272</td><td align="left">0.1104</td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>Mean, standard error of mean (SEM), and <italic>P </italic>value between estrogen receptor-negative (ER-) and estrogen receptor-positive (ER+) breast cancers are presented for <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5 </italic>expression in the analyzed datasets. <sup>a</sup>Uppsala cohort. * Subset of samples with <italic>keratin-5 </italic>data.</p></table-wrap-foot></table-wrap></sec><sec><title>A novel dual-gene signature in basal breast cancer</title><p>Analysis of 507 ER-negative and 1,356 ER-positive breast cancer patients revealed that <italic>keratin-5 </italic>associated with ER-negative breast cancers (Figure <xref ref-type="fig" rid="F4">4a</xref>) in seven out of 13 datasets, and that <italic>Notch-1 </italic>associated with ER-negative breast cancers in nine out of 16 datasets (Table <xref ref-type="table" rid="T2">2</xref>). Pooled estimates of Pearson's correlation coefficient between <italic>Notch-1</italic>/<italic>keratin-5 </italic>were 0.3315 and 0.2043 for ER-negative and ER-positive breast cancers, respectively (<italic>P </italic>= 0.04) (Figure <xref ref-type="fig" rid="F4">4a</xref>). Similarly, <italic>survivin </italic>and <italic>keratin-5 </italic>co-segregated in ER-negative breast cancer, with a pooled estimate of Pearson's correlation coefficient of 0.1314 for ER-negative breast cancer and of -0.2408 for ER-positive breast cancer (<italic>P </italic>&#x0003c; 0.0001) (Figure <xref ref-type="fig" rid="F4">4b</xref>). A negative correlation exists between <italic>survivin </italic>and <italic>keratin-5 </italic>in ER-positive breast cancers most probably because other transcriptional and nontranscriptional mechanisms are likely to control survivin expression in nonbasal cancers (Figure <xref ref-type="fig" rid="F4">4b</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Co-segregation of <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5 </italic>in breast cancer. Pearson's correlation coefficient and the 95% confidence interval were calculated from the analysis of individual datasets. <bold>(a) </bold><italic>Notch-1</italic>/<italic>keratin-5</italic>. <bold>(b) </bold><italic>Survivin</italic>/<italic>keratin-5</italic>. <bold>(c) </bold><italic>Notch-1/survivin</italic>. For study details, see Table 2. ER, estrogen receptor.</p></caption><graphic xlink:href="bcr2200-4"/></fig><p>Analysis of 604 ER-negative and 1,463 ER-positive breast cancer patients revealed that <italic>survivin </italic>segregated with ER-negative tumors (two-tailed <italic>P </italic>&#x0003c; 0.05) in 12 out of 16 cohorts (Table <xref ref-type="table" rid="T2">2</xref>). The Pearson's correlation coefficients between <italic>Notch-1 </italic>and <italic>survivin </italic>were 0.1804 and -0.0674 for ER-negative and ER-positive breast cancers, respectively (<italic>P </italic>&#x0003c; 0.0001) (Figure <xref ref-type="fig" rid="F4">4c</xref>).</p></sec><sec><title>Notch-1 regulation of survivin expression</title><p>Consistent with the model presented above, recent studies have shown that survivin may function as a direct transcriptional target of Notch-1, thus controlling mitotic transition and resistance to apoptosis in breast cancer [<xref ref-type="bibr" rid="B35">35</xref>]. In agreement with these data, transfection of ER-negative breast cancer MDA-MB-231 cells with NIC resulted in increased survivin expression, as determined by western blotting, whereas acute siRNA silencing of Notch was associated with reduced survivin levels and induction of apoptosis (data not shown). Similarly, inhibition of Notch signaling by a pharmacologic inhibitor of &#x003b3;-secretase suppressed <italic>survivin </italic>gene expression (data not shown), validating the identity of survivin as a direct transcriptional target of Notch in breast cancer cells [<xref ref-type="bibr" rid="B35">35</xref>].</p></sec></sec><sec><title>Discussion</title><p>In the present study, we have shown that Notch-1 is preferentially expressed in breast cancer, as compared with normal tissues, segregates with basal disease, and correlates with abbreviated survival. In a meta-analysis of multiple, independent microarray datasets, <italic>Notch-1</italic>, <italic>survivin</italic>, and <italic>keratin-5 </italic>selectively co-associated with ER-negative versus ER-positive breast cancer patients. Consistent with recent observations [<xref ref-type="bibr" rid="B35">35</xref>], survivin was validated as a direct transcriptional target of Notch in model ER-negative breast cancer cells.</p><p>These findings add to an in-depth molecular classification of breast cancer [<xref ref-type="bibr" rid="B4">4</xref>] &#x02013; and in particular basal breast cancer, a disease variant that still poses significant therapeutic challenges. In addition to high-risk genetics [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>] and aggressive histologic features [<xref ref-type="bibr" rid="B5">5</xref>], it has been speculated that basal breast cancer may originate from a progenitor/stem cell compartment in the basal mammary epithelium. This is consistent with a proposed role for Notch in mammary progenitor cell differentiation and maintenance [<xref ref-type="bibr" rid="B39">39</xref>], and potentially in the early events of their transformation [<xref ref-type="bibr" rid="B40">40</xref>]. Such a pathway may not be exclusively limited to breast cancer [<xref ref-type="bibr" rid="B20">20</xref>], given that deregulated Notch signaling has been implicated as a driver of disparate malignancies [<xref ref-type="bibr" rid="B15">15</xref>], as promoting aberrant cell cycle progression [<xref ref-type="bibr" rid="B41">41</xref>], and associated with unfavorable outcome [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>In this context, survivin appears ideally suited to function as a pleiotropic, <italic>direct </italic>Notch effector gene in clinically aggressive breast cancer [<xref ref-type="bibr" rid="B2">2</xref>]. At the molecular level, this involves occupancy of discrete RPB-J&#x003ba; binding element(s) in the <italic>survivin </italic>promoter upon Notch activation, which results in transcriptional upregulation of survivin levels, inhibition of apoptosis, and acceleration of mitotic transitions selectively in ER-negative breast cancer cells [<xref ref-type="bibr" rid="B35">35</xref>]. Whether deregulation of a Notch&#x02013;survivin signaling axis is preferentially operative in a progenitor/stem cell compartment is currently not known.</p><p>Intriguing, however, is that another developmental gene expression pathway (that is, Wnt/&#x003b2;-catenin) has been implicated in controlling survivin levels in intestinal crypt progenitor cells, potentially contributing to colon cancer [<xref ref-type="bibr" rid="B42">42</xref>], and that survivin expression been consistently associated with stemness gene signatures of mesenchymal [<xref ref-type="bibr" rid="B43">43</xref>], neuronal [<xref ref-type="bibr" rid="B44">44</xref>], and skin [<xref ref-type="bibr" rid="B45">45</xref>] progenitor cells. Results of conditional knockout studies appear to support this model, as heterozygous deletion of survivin produced complete bone marrow ablation, loss of hematopoietic progenitor/stem cells, and rapid animal mortality [<xref ref-type="bibr" rid="B22">22</xref>]. This pathway may have a clear link to human disease, as lineage-specific methylation and silencing of the <italic>survivin </italic>gene has been linked to bone marrow depletion in myelodsyplastic syndrome [<xref ref-type="bibr" rid="B46">46</xref>]. With respect to breast cancer, Notch-dependent upregulation of survivin [<xref ref-type="bibr" rid="B35">35</xref>] may broadly suppress apoptosis, deregulate cell cycle progression [<xref ref-type="bibr" rid="B21">21</xref>], and ultimately promote resistance to mainstay therapeutic agents in this disease, such as taxanes [<xref ref-type="bibr" rid="B47">47</xref>] and DNA damaging agents [<xref ref-type="bibr" rid="B48">48</xref>].</p><p>Although the diagnosis of triple-negative, basal breast cancer is straightforward [<xref ref-type="bibr" rid="B6">6</xref>], these patients continue to pose therapeutic challenges for the aggressive nature of the disease, which is prone to relapse, and the lack of appropriate, molecularly targeted agents [<xref ref-type="bibr" rid="B10">10</xref>]. Based on the findings presented herein, it may be possible to envision antagonists of Notch [<xref ref-type="bibr" rid="B49">49</xref>] and of survivin [<xref ref-type="bibr" rid="B21">21</xref>] as potential molecular therapy for basal breast cancer patients. Agents that interfere with Notch signaling inhibit the enzyme &#x003b3;-secretase, which is responsible for the activating intracellular cleavage of Notch upon ligand binding at the cell surface [<xref ref-type="bibr" rid="B15">15</xref>]. Despite concerns of specificity [<xref ref-type="bibr" rid="B50">50</xref>] and potential intestinal toxicity [<xref ref-type="bibr" rid="B51">51</xref>], &#x003b3;-secretase inhibitor molecules are being tested as molecular therapy for leukemic patients harboring activating mutations in Notch [<xref ref-type="bibr" rid="B49">49</xref>]. In our recent studies, systemic administration of a peptidyl &#x003b3;-secretase inhibitor significantly inhibited breast cancer growth <italic>in vivo</italic>, and almost completely abolished metastatic dissemination, with no detectable organ or systemic toxicity [<xref ref-type="bibr" rid="B35">35</xref>]. Antagonists of survivin are also available in the clinic, producing encouraging patient responses and manageable toxicity in early-phase clinical trials [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>In summary, we have extended recent <italic>in vitro </italic>observations [<xref ref-type="bibr" rid="B35">35</xref>] and have validated the existence of a functional Notch-1/survivin signaling axis, <italic>in vivo</italic>, selectively in patients with basal breast cancer. Targeting Notch-1 signaling in model breast cancer cells lowered survivin levels, resulting in pronounced anti-tumor effects [<xref ref-type="bibr" rid="B35">35</xref>]. Taken together with the stringent correlation reported here across disparate tumor series, <italic>in vivo</italic>, this observation raises the possibility that basal breast cancer cells may selectively become dependent on, or addicted to, Notch/survivin signaling for their maintenance [<xref ref-type="bibr" rid="B52">52</xref>]. Although it is unclear to what extent oncogene addiction maintains the malignant phenotype <italic>in vivo </italic>[<xref ref-type="bibr" rid="B53">53</xref>], antagonists of such pathways have produced impressive clinical responses, at least in certain patient subsets [<xref ref-type="bibr" rid="B54">54</xref>]. A similar rationale may be envisioned here for targeting Notch and survivin in basal breast cancer patients, especially if this pathway can be disabled in a progenitor/stem cell compartment, acting as a potential disease reservoir contributing to a high incidence of relapses.</p></sec><sec><title>Conclusion</title><p>Expression of Notch-1 and survivin segregates with clinically aggressive and recurrence-prone basal breast cancer. Antagonists of these signaling pathways may be considered as targeted, novel molecular therapy of basal breast cancer.</p></sec><sec><title>Abbreviations</title><p>ER: estrogen receptor; HER-2: human epidermal growth factor receptor 2; NIC: Notch-1 intracellular domain; PBS: phosphate-buffered saline; siRNA: small interfering RNA.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CWL, JP, and MG carried out experiments of survivin and Notch expression and function in breast cancer as well as immunohistochemical analysis in primary normal and tumor samples. KS performed the hierarchical clustering experiments. QL and C-CH provided statistical evaluation and interpretation of the microarray and Pearson analysis data. AK analyzed the immunohistochemistry of human breast tumor samples and provided clinical and pathological data. DCA participated in the design and coordination of the study. CWL and DCA wrote the paper. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The present work is supported by grants from the National Institutes of Health: CA132622 (CWL), and HL54131, CA90917, and CA78810 (DCA).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Gurney</surname><given-names>A</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Lewicki</surname><given-names>J</given-names></name><name><surname>Shedden</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name></person-group><article-title>The prognostic role of a gene signature from tumorigenic breast-cancer cells</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">17229949</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa063994</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Shak</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Cronin</surname><given-names>M</given-names></name><name><surname>Baehner</surname><given-names>FL</given-names></name><name><surname>Walker</surname><given-names>MG</given-names></name><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>T</given-names></name><name><surname>Hiller</surname><given-names>W</given-names></name><name><surname>Fisher</surname><given-names>ER</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><article-title>A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2817</fpage><lpage>2826</lpage><pub-id pub-id-type="pmid">15591335</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa041588</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Peterse</surname><given-names>HL</given-names></name><name><surname>Kooy</surname><given-names>K van der</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">11823860</pub-id><pub-id pub-id-type="doi">10.1038/415530a</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name></person-group><article-title>Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">17585334</pub-id><pub-id pub-id-type="doi">10.1038/nrc2173</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da Silva</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name></person-group><article-title>Demystifying basal-like breast carcinomas</article-title><source>J Clin Pathol</source><year>2007</year><volume>60</volume><fpage>1328</fpage><lpage>1332</lpage><pub-id pub-id-type="pmid">17496191</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2006.041731</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Hsu</surname><given-names>FD</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Cheang</surname><given-names>M</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Dressler</surname><given-names>L</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Ragaz</surname><given-names>J</given-names></name><name><surname>Gown</surname><given-names>AM</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>5367</fpage><lpage>5374</lpage><pub-id pub-id-type="pmid">15328174</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0220</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><name><surname>Pollack</surname><given-names>JR</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Fluge</surname><given-names>O</given-names></name><name><surname>Pergamenschikov</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>SX</given-names></name><name><surname>Lonning</surname><given-names>PE</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">10963602</pub-id><pub-id pub-id-type="doi">10.1038/35021093</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Neo</surname><given-names>SY</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Korn</surname><given-names>EL</given-names></name><name><surname>Long</surname><given-names>PM</given-names></name><name><surname>Jazaeri</surname><given-names>A</given-names></name><name><surname>Martiat</surname><given-names>P</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>10393</fpage><lpage>10398</lpage><pub-id pub-id-type="pmid">12917485</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1732912100</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Rijn</surname><given-names>M van de</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Thorsen</surname><given-names>T</given-names></name><name><surname>Quist</surname><given-names>H</given-names></name><name><surname>Matese</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Eystein Lonning</surname><given-names>P</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="pmid">11553815</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cleator</surname><given-names>S</given-names></name><name><surname>Heller</surname><given-names>W</given-names></name><name><surname>Coombes</surname><given-names>RC</given-names></name></person-group><article-title>Triple-negative breast cancer: therapeutic options</article-title><source>Lancet Oncol</source><year>2007</year><volume>8</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">17329194</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(07)70074-8</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Albanell</surname><given-names>J</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Gascon</surname><given-names>P</given-names></name><name><surname>Guillem</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Sauleda</surname><given-names>S</given-names></name><name><surname>Marimon</surname><given-names>I</given-names></name><name><surname>Tabernero</surname><given-names>JM</given-names></name><name><surname>Koehler</surname><given-names>MT</given-names></name><name><surname>Rojo</surname><given-names>F</given-names></name></person-group><article-title>Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5323</fpage><lpage>5333</lpage><pub-id pub-id-type="pmid">15939921</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.08.326</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name><name><surname>Sawyer</surname><given-names>L</given-names></name><name><surname>Gatti</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>DT</given-names></name><name><surname>Collichio</surname><given-names>F</given-names></name><name><surname>Ollila</surname><given-names>DW</given-names></name><name><surname>Sartor</surname><given-names>CI</given-names></name><name><surname>Graham</surname><given-names>ML</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>2329</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">17438091</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1109</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dontu</surname><given-names>G</given-names></name><name><surname>El-Ashry</surname><given-names>D</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name></person-group><article-title>Breast cancer, stem/progenitor cells and the estrogen receptor</article-title><source>Trends Endocrinol Metab</source><year>2004</year><volume>15</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15223047</pub-id><pub-id pub-id-type="doi">10.1016/j.tem.2004.05.011</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt/beta-catenin signaling in development and disease</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>469</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">17081971</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.10.018</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>SJ</given-names></name></person-group><article-title>Notch signalling: a simple pathway becomes complex</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><fpage>678</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">16921404</pub-id><pub-id pub-id-type="doi">10.1038/nrm2009</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buono</surname><given-names>KD</given-names></name><name><surname>Robinson</surname><given-names>GW</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Stanley</surname><given-names>P</given-names></name><name><surname>Tanigaki</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Hennighausen</surname><given-names>L</given-names></name></person-group><article-title>The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy</article-title><source>Dev Biol</source><year>2006</year><volume>293</volume><fpage>565</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">16581056</pub-id><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.02.043</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sansone</surname><given-names>P</given-names></name><name><surname>Storci</surname><given-names>G</given-names></name><name><surname>Tavolari</surname><given-names>S</given-names></name><name><surname>Guarnieri</surname><given-names>T</given-names></name><name><surname>Giovannini</surname><given-names>C</given-names></name><name><surname>Taffurelli</surname><given-names>M</given-names></name><name><surname>Ceccarelli</surname><given-names>C</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Paterini</surname><given-names>P</given-names></name><name><surname>Marcu</surname><given-names>KB</given-names></name><name><surname>Chieco</surname><given-names>P</given-names></name><name><surname>Bonafe</surname><given-names>M</given-names></name></person-group><article-title>IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>3988</fpage><lpage>4002</lpage><pub-id pub-id-type="pmid">18060036</pub-id><pub-id pub-id-type="doi">10.1172/JCI32533</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reedijk</surname><given-names>M</given-names></name><name><surname>Odorcic</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>N</given-names></name><name><surname>McCready</surname><given-names>DR</given-names></name><name><surname>Lockwood</surname><given-names>G</given-names></name><name><surname>Egan</surname><given-names>SE</given-names></name></person-group><article-title>High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>8530</fpage><lpage>8537</lpage><pub-id pub-id-type="pmid">16166334</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1069</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>P</given-names></name><name><surname>Miao</surname><given-names>H</given-names></name><name><surname>D'Souza</surname><given-names>G</given-names></name><name><surname>Osipo</surname><given-names>C</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Mascarenhas</surname><given-names>J</given-names></name><name><surname>Wyatt</surname><given-names>D</given-names></name><name><surname>Antico</surname><given-names>G</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Rajan</surname><given-names>P</given-names></name><name><surname>Hicks</surname><given-names>C</given-names></name><name><surname>Siziopikou</surname><given-names>K</given-names></name><name><surname>Selvaggi</surname><given-names>S</given-names></name><name><surname>Bashir</surname><given-names>A</given-names></name><name><surname>Bhandari</surname><given-names>D</given-names></name><name><surname>Marchese</surname><given-names>A</given-names></name><name><surname>Lendahl</surname><given-names>U</given-names></name><name><surname>Qin</surname><given-names>J-Z</given-names></name><name><surname>Tonetti</surname><given-names>DA</given-names></name><name><surname>Albain</surname><given-names>K</given-names></name><name><surname>Nickoloff</surname><given-names>BJ</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name></person-group><article-title>Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>5226</fpage><lpage>5235</lpage><pub-id pub-id-type="pmid">18593923</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5744</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stylianou</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>RB</given-names></name><name><surname>Brennan</surname><given-names>K</given-names></name></person-group><article-title>Aberrant activation of notch signaling in human breast cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>1517</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">16452208</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3054</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin, cancer networks and pathway-directed drug discovery</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">18075512</pub-id><pub-id pub-id-type="doi">10.1038/nrc2293</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>CG</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Mularski</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Gurbuxani</surname><given-names>S</given-names></name><name><surname>Crispino</surname><given-names>JD</given-names></name></person-group><article-title>Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><fpage>1603</fpage><lpage>1611</lpage><pub-id pub-id-type="pmid">17576776</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Beltrami</surname><given-names>E</given-names></name><name><surname>Wall</surname><given-names>NR</given-names></name><name><surname>Plescia</surname><given-names>J</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">15489959</pub-id></citation></ref><ref id="B24"><citation citation-type="other"><article-title>University of North Carolina Microarray Database</article-title><ext-link ext-link-type="uri" xlink:href="https://genome.unc.edu"/></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herschkowitz</surname><given-names>JI</given-names></name><name><surname>Simin</surname><given-names>K</given-names></name><name><surname>Weigman</surname><given-names>VJ</given-names></name><name><surname>Mikaelian</surname><given-names>I</given-names></name><name><surname>Usary</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Rasmussen</surname><given-names>KE</given-names></name><name><surname>Jones</surname><given-names>LP</given-names></name><name><surname>Assefnia</surname><given-names>S</given-names></name><name><surname>Chandrasekharan</surname><given-names>S</given-names></name><name><surname>Backlund</surname><given-names>MG</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Khramtsov</surname><given-names>AI</given-names></name><name><surname>Bastein</surname><given-names>R</given-names></name><name><surname>Quackenbush</surname><given-names>J</given-names></name><name><surname>Glazer</surname><given-names>RI</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name><name><surname>Green</surname><given-names>JE</given-names></name><name><surname>Kopelovich</surname><given-names>L</given-names></name><name><surname>Furth</surname><given-names>PA</given-names></name><name><surname>Palazzo</surname><given-names>JP</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Bernard</surname><given-names>PS</given-names></name><name><surname>Churchill</surname><given-names>GA</given-names></name><name><surname>Van Dyke</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><fpage>R76</fpage><pub-id pub-id-type="pmid">17493263</pub-id><pub-id pub-id-type="doi">10.1186/gb-2007-8-5-r76</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name></person-group><article-title>Cluster analysis and display of genome-wide expression patterns</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>14863</fpage><lpage>14868</lpage><pub-id pub-id-type="pmid">9843981</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.25.14863</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saldanha</surname><given-names>AJ</given-names></name></person-group><article-title>Java Treeview &#x02013; extensible visualization of microarray data</article-title><source>Bioinformatics</source><year>2004</year><volume>20</volume><fpage>3246</fpage><lpage>3248</lpage><pub-id pub-id-type="pmid">15180930</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth349</pub-id></citation></ref><ref id="B28"><citation citation-type="other"><article-title>SAS Institute JMP Software</article-title><ext-link ext-link-type="uri" xlink:href="http://www.jmp.com"/></citation></ref><ref id="B29"><citation citation-type="other"><article-title>Oncomine</article-title><ext-link ext-link-type="uri" xlink:href="http://www.oncomine.org"/></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><name><surname>Deshpande</surname><given-names>N</given-names></name><name><surname>Varambally</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Barrette</surname><given-names>T</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>ONCOMINE: a cancer microarray database and integrated data-mining platform</article-title><source>Neoplasia</source><year>2004</year><volume>6</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15068665</pub-id></citation></ref><ref id="B31"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kleibaum</surname><given-names>DG</given-names></name><name><surname>Kupper</surname><given-names>LL</given-names></name><name><surname>Muller</surname><given-names>KE</given-names></name><name><surname>Nizam</surname><given-names>A</given-names></name></person-group><source>Applied regression analysis and other multivariable methods</source><year>1998</year><publisher-name>Pacific Grove, CA: Duxbury Press</publisher-name><fpage>96</fpage><lpage>98</lpage></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turashvili</surname><given-names>G</given-names></name><name><surname>Bouchal</surname><given-names>J</given-names></name><name><surname>Baumforth</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Dziechciarkova</surname><given-names>M</given-names></name><name><surname>Ehrmann</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Fridman</surname><given-names>E</given-names></name><name><surname>Skarda</surname><given-names>J</given-names></name><name><surname>Srovnal</surname><given-names>J</given-names></name><name><surname>Hajduch</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>Kolar</surname><given-names>Z</given-names></name></person-group><article-title>Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis</article-title><source>BMC Cancer</source><year>2007</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="pmid">17389037</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-7-55</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">3802833</pub-id><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Mitosis-independent survivin gene expression in vivo and regulation by p53</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>3392</fpage><lpage>3395</lpage><pub-id pub-id-type="pmid">16585159</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4537</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Raskett</surname><given-names>CM</given-names></name><name><surname>Prudovsky</surname><given-names>I</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>5273</fpage><lpage>5281</lpage><pub-id pub-id-type="pmid">18593928</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6673</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Nowels</surname><given-names>KW</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Bukholm</surname><given-names>IK</given-names></name><name><surname>Karesen</surname><given-names>R</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name></person-group><article-title>Different gene expression patterns in invasive lobular and ductal carcinomas of the breast</article-title><source>Mol Biol Cell</source><year>2004</year><volume>15</volume><fpage>2523</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">15034139</pub-id><pub-id pub-id-type="doi">10.1091/mbc.E03-11-0786</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Johansson</surname><given-names>P</given-names></name><name><surname>Holm</surname><given-names>K</given-names></name><name><surname>Gruvberger-Saal</surname><given-names>SK</given-names></name><name><surname>She</surname><given-names>QB</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name><name><surname>Koujak</surname><given-names>S</given-names></name><name><surname>Ferrando</surname><given-names>AA</given-names></name><name><surname>Malmstrom</surname><given-names>P</given-names></name><name><surname>Memeo</surname><given-names>L</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Ringner</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name></person-group><article-title>Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><fpage>7564</fpage><lpage>7569</lpage><pub-id pub-id-type="pmid">17452630</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0702507104</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Ganesan</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name></person-group><article-title>A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>3288</fpage><lpage>3296</lpage><pub-id pub-id-type="pmid">16740749</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1530</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raouf</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>To</surname><given-names>K</given-names></name><name><surname>Stingl</surname><given-names>J</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Barbara</surname><given-names>M</given-names></name><name><surname>Iscove</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Emerman</surname><given-names>J</given-names></name><name><surname>Aparicio</surname><given-names>S</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Eaves</surname><given-names>C</given-names></name></person-group><article-title>Transcriptome analysis of the normal human mammary cell commitment and differentiation process</article-title><source>Cell Stem Cell</source><year>2008</year><volume>3</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">18593563</pub-id><pub-id pub-id-type="doi">10.1016/j.stem.2008.05.018</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farnie</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>RB</given-names></name><name><surname>Spence</surname><given-names>K</given-names></name><name><surname>Pinnock</surname><given-names>N</given-names></name><name><surname>Brennan</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>NG</given-names></name><name><surname>Bundred</surname><given-names>NJ</given-names></name></person-group><article-title>Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><fpage>616</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">17440163</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djk133</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronchini</surname><given-names>C</given-names></name><name><surname>Capobianco</surname><given-names>AJ</given-names></name></person-group><article-title>Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic)</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>5925</fpage><lpage>5934</lpage><pub-id pub-id-type="pmid">11486031</pub-id><pub-id pub-id-type="doi">10.1128/MCB.21.17.5925-5934.2001</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>PJ</given-names></name><name><surname>Plescia</surname><given-names>J</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Survivin and molecular pathogenesis of colorectal cancer</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">12885482</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13910-4</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taubert</surname><given-names>H</given-names></name><name><surname>Wurl</surname><given-names>P</given-names></name><name><surname>Greither</surname><given-names>T</given-names></name><name><surname>Kappler</surname><given-names>M</given-names></name><name><surname>Bache</surname><given-names>M</given-names></name><name><surname>Bartel</surname><given-names>F</given-names></name><name><surname>Kehlen</surname><given-names>A</given-names></name><name><surname>Lautenschlager</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>LC</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name><name><surname>Fussel</surname><given-names>S</given-names></name><name><surname>Meye</surname><given-names>A</given-names></name><name><surname>Bohnke</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Holzhausen</surname><given-names>HJ</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name></person-group><article-title>Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>7170</fpage><lpage>7174</lpage><pub-id pub-id-type="pmid">17525744</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210530</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pennartz</surname><given-names>S</given-names></name><name><surname>Belvindrah</surname><given-names>R</given-names></name><name><surname>Tomiuk</surname><given-names>S</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Conradt</surname><given-names>M</given-names></name><name><surname>Bosio</surname><given-names>A</given-names></name><name><surname>Cremer</surname><given-names>H</given-names></name></person-group><article-title>Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis</article-title><source>Mol Cell Neurosci</source><year>2004</year><volume>25</volume><fpage>692</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">15080897</pub-id><pub-id pub-id-type="doi">10.1016/j.mcn.2003.12.011</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marconi</surname><given-names>A</given-names></name><name><surname>Dallaglio</surname><given-names>K</given-names></name><name><surname>Lotti</surname><given-names>R</given-names></name><name><surname>Vaschieri</surname><given-names>C</given-names></name><name><surname>Truzzi</surname><given-names>F</given-names></name><name><surname>Fantini</surname><given-names>F</given-names></name><name><surname>Pincelli</surname><given-names>C</given-names></name></person-group><article-title>Survivin identifies keratinocyte stem cells and it is down-regulated by anti-{beta}1 integrin during anoikis</article-title><source>Stem Cells</source><year>2006</year><volume>25</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">17008426</pub-id><pub-id pub-id-type="doi">10.1634/stemcells.2006-0165</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopfer</surname><given-names>O</given-names></name><name><surname>Komor</surname><given-names>M</given-names></name><name><surname>Koehler</surname><given-names>IS</given-names></name><name><surname>Schulze</surname><given-names>M</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name></person-group><article-title>DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation</article-title><source>Exp Hematol</source><year>2007</year><volume>35</volume><fpage>712</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">17577921</pub-id><pub-id pub-id-type="doi">10.1016/j.exphem.2007.01.054</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>DS</given-names></name><name><surname>Wall</surname><given-names>NR</given-names></name><name><surname>Porter</surname><given-names>AC</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>A p34(cdc2) survival checkpoint in cancer</article-title><source>Cancer Cell</source><year>2002</year><volume>2</volume><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12150824</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00084-3</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>JC</given-names></name><name><surname>Dohi</surname><given-names>T</given-names></name><name><surname>Raskett</surname><given-names>CM</given-names></name><name><surname>Kowalik</surname><given-names>TF</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Activated checkpoint kinase 2 provides a survival signal for tumor cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>11576</fpage><lpage>11579</lpage><pub-id pub-id-type="pmid">17178848</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3095</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>TL</given-names></name></person-group><article-title>Notch signaling, gamma-secretase inhibitors, and cancer therapy</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>1879</fpage><lpage>1882</lpage><pub-id pub-id-type="pmid">17332312</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3958</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fortini</surname><given-names>ME</given-names></name></person-group><article-title>Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling</article-title><source>Nat Rev Mol Cell Biol</source><year>2002</year><volume>3</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">12209127</pub-id><pub-id pub-id-type="doi">10.1038/nrm910</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>GT</given-names></name><name><surname>Manfra</surname><given-names>D</given-names></name><name><surname>Poulet</surname><given-names>FM</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Josien</surname><given-names>H</given-names></name><name><surname>Bara</surname><given-names>T</given-names></name><name><surname>Engstrom</surname><given-names>L</given-names></name><name><surname>Pinzon-Ortiz</surname><given-names>M</given-names></name><name><surname>Fine</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Higgins</surname><given-names>GA</given-names></name><name><surname>Parker</surname><given-names>EM</given-names></name></person-group><article-title>Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>12876</fpage><lpage>12882</lpage><pub-id pub-id-type="pmid">14709552</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M311652200</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>IB</given-names></name><name><surname>Joe</surname><given-names>AK</given-names></name></person-group><article-title>Mechanisms of disease: Oncogene addiction &#x02013; a rationale for molecular targeting in cancer therapy</article-title><source>Nat Clin Pract Oncol</source><year>2006</year><volume>3</volume><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">16894390</pub-id><pub-id pub-id-type="doi">10.1038/ncponc0558</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Berns</surname><given-names>A</given-names></name></person-group><article-title>Oncogene addiction; Sometimes a temporary slavery</article-title><source>Cancer Cell</source><year>2004</year><volume>6</volume><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">15607957</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SV</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Epidermal growth factor receptor mutations in lung cancer</article-title><source>Nat Rev Cancer</source><year>2007</year><volume>7</volume><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">17318210</pub-id><pub-id pub-id-type="doi">10.1038/nrc2088</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>DeVries</surname><given-names>S</given-names></name><name><surname>Fridlyand</surname><given-names>J</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Roydasgupta</surname><given-names>R</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Lapuk</surname><given-names>A</given-names></name><name><surname>Neve</surname><given-names>RM</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Ryder</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Feiler</surname><given-names>H</given-names></name><name><surname>Tokuyasu</surname><given-names>T</given-names></name><name><surname>Kingsley</surname><given-names>C</given-names></name><name><surname>Dairkee</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chew</surname><given-names>K</given-names></name><name><surname>Pinkel</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Ljung</surname><given-names>BM</given-names></name><name><surname>Esserman</surname><given-names>L</given-names></name><name><surname>Albertson</surname><given-names>DG</given-names></name><name><surname>Waldman</surname><given-names>FM</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><article-title>Genomic and transcriptional aberrations linked to breast cancer pathophysiologies</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><fpage>529</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">17157792</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.009</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Piette</surname><given-names>F</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lallemand</surname><given-names>F</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>d'Assignies</surname><given-names>MS</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>3207</fpage><lpage>3214</lpage><pub-id pub-id-type="pmid">17545524</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2765</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Cervera</surname><given-names>N</given-names></name><name><surname>Finetti</surname><given-names>P</given-names></name><name><surname>Esteyries</surname><given-names>S</given-names></name><name><surname>Esterni</surname><given-names>B</given-names></name><name><surname>Adelaide</surname><given-names>J</given-names></name><name><surname>Xerri</surname><given-names>L</given-names></name><name><surname>Viens</surname><given-names>P</given-names></name><name><surname>Jacquemier</surname><given-names>J</given-names></name><name><surname>Charafe-Jauffret</surname><given-names>E</given-names></name><name><surname>Chaffanet</surname><given-names>M</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Bertucci</surname><given-names>F</given-names></name></person-group><article-title>Prognosis and gene expression profiling of 20q13-amplified breast cancers</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>4533</fpage><lpage>4544</lpage><pub-id pub-id-type="pmid">16899599</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2339</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Mejia</surname><given-names>JA</given-names></name><name><surname>Booser</surname><given-names>D</given-names></name><name><surname>Theriault</surname><given-names>RL</given-names></name><name><surname>Buzdar</surname><given-names>AU</given-names></name><name><surname>Dempsey</surname><given-names>PJ</given-names></name><name><surname>Rouzier</surname><given-names>R</given-names></name><name><surname>Sneige</surname><given-names>N</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Vidaurre</surname><given-names>T</given-names></name><name><surname>Gomez</surname><given-names>HL</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name></person-group><article-title>Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>4236</fpage><lpage>4244</lpage><pub-id pub-id-type="pmid">16896004</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.05.6861</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivshina</surname><given-names>AV</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Senko</surname><given-names>O</given-names></name><name><surname>Mow</surname><given-names>B</given-names></name><name><surname>Putti</surname><given-names>TC</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Lindahl</surname><given-names>T</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Nordgren</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Kuznetsov</surname><given-names>VA</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name></person-group><article-title>Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>10292</fpage><lpage>10301</lpage><pub-id pub-id-type="pmid">17079448</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4414</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Vega</surname><given-names>VB</given-names></name><name><surname>Vergara</surname><given-names>L</given-names></name><name><surname>Ploner</surname><given-names>A</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Klaar</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name></person-group><article-title>An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>13550</fpage><lpage>13555</lpage><pub-id pub-id-type="pmid">16141321</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0506230102</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>Gupta</surname><given-names>GP</given-names></name><name><surname>Siegel</surname><given-names>PM</given-names></name><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Shu</surname><given-names>W</given-names></name><name><surname>Giri</surname><given-names>DD</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>Genes that mediate breast cancer metastasis to lung</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16049480</pub-id><pub-id pub-id-type="doi">10.1038/nature03799</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>De Nicolo</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Iglehart</surname><given-names>JD</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name></person-group><article-title>X chromosomal abnormalities in basal-like human breast cancer</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">16473279</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2006.01.013</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Wirapati</surname><given-names>P</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>S</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Nordgren</surname><given-names>H</given-names></name><name><surname>Farmer</surname><given-names>P</given-names></name><name><surname>Praz</surname><given-names>V</given-names></name><name><surname>Haibe-Kains</surname><given-names>B</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Peterse</surname><given-names>H</given-names></name><name><surname>Nuyten</surname><given-names>D</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name><name><surname>Vijver</surname><given-names>MJ Van de</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name></person-group><article-title>Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">16478745</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Voskuil</surname><given-names>DW</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Peterse</surname><given-names>JL</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Parrish</surname><given-names>M</given-names></name><name><surname>Atsma</surname><given-names>D</given-names></name><name><surname>Witteveen</surname><given-names>A</given-names></name><name><surname>Glas</surname><given-names>A</given-names></name><name><surname>Delahaye</surname><given-names>L</given-names></name><name><surname>Velde</surname><given-names>T van der</given-names></name><name><surname>Bartelink</surname><given-names>H</given-names></name><name><surname>Rodenhuis</surname><given-names>S</given-names></name><name><surname>Rutgers</surname><given-names>ET</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="pmid">12490681</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sieuwerts</surname><given-names>AM</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Talantov</surname><given-names>D</given-names></name><name><surname>Timmermans</surname><given-names>M</given-names></name><name><surname>Meijer-van Gelder</surname><given-names>ME</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jatkoe</surname><given-names>T</given-names></name><name><surname>Berns</surname><given-names>EM</given-names></name><name><surname>Atkins</surname><given-names>D</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name></person-group><article-title>Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">15721472</pub-id></citation></ref></ref-list></back></article> 